Seroquel XR in the Long Term Treatment of Schizophrenia (SereNIS)

AstraZeneca

Status: Completed

Conditions: Relapse in Schizophrenia

Study type: Observational

Funder types: Industry

Identifiers

NCT01202617

NIS-NHU-SER-2010/1

Details and patient eligibility

About

The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improves the relapse prevention in schizophrenic outpatients

Enrollment: 1,606 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• schizophrenic outpatients on at least 600 mg Seroquel XR treatment for at least 1 month

Exclusion criteria

• Severe cerebro- and cardiovascular disease, severe hepatic impairment, gravidity

Trial design

1,606 participants in 1 patient group

Schizophrenic outpatients between 18 & 70 years of age